Adipotide (FTPP) protocol

No established human protocol

Phase	How often	Dose	Units	Notes

No established human protocol. Published animal studies used ~0.43–5 mg/kg IV twice weekly for short courses, with renal toxicity at higher doses. There is no validated, safe human dosing; this compound is included for completeness, not as a recommended protocol.

What to expect

Unknown in humans. Animal data showed rapid fat loss but with kidney injury, the risk/benefit is not established.

Men & women

Unisex mechanism, but the riskiest entry here (kidney toxicity in primates). No human data; contraindicated in pregnancy.

Recommended mixes

Vial	Water	Strength
2 mg	0.4 mL	5 mg/mL
5 mg	1 mL	5 mg/mL
10 mg	2 mL	5 mg/mL

2 mg: No validated human dose, figures are research-derived only

Storage

PowderFreeze-dried: -4°F.
MixedReconstituted: 36–46°F, short-dated.

Don't use if: Any kidney disease or reduced renal function · Dehydration or conditions causing volume depletion · Pregnancy and lactation · Concurrent nephrotoxic agents (NSAIDs, certain antibiotics, contrast)

Stop if you notice

Any rise in creatinine or fall in eGFR
Reduced urine output, flank pain, or edema
Any sign of systemic illness

Side effects

Renal toxicity (primate data), dehydration, electrolyte disturbance. Human side-effect profile unknown.

Drug interactions

Other nephrotoxic drugs: compounded kidney risk, avoid. Diuretics / dehydration: worsen renal stress.

Labs

Renal function (creatinine, eGFR, urinalysis) before, during, and after; mandatory if used at all. Electrolytes and hydration status. Out of range? Any creatinine rise or eGFR drop = kidney injury starting → stop immediately (this is the defining risk).

What these labs mean →

Warnings

Dose-dependent renal toxicity in primate studies, the central safety concern. No human safety, efficacy, or dosing data. Proapoptotic mechanism is non-selective enough to warrant serious caution. Not an approved drug anywhere.

Patient education

This is the highest-risk compound in this section, included for completeness, not endorsement. The proven harm in animals was kidney injury; human safety is unknown. Safer, proven fat-loss tools (GLP-1s, AOD-9604) exist; prefer them. If considered at all, only under medical supervision with renal monitoring.

These apply on top of the universal safety rules.

Avoid with

Any pre-existing kidney disease

Dehydration

Pregnancy

Concurrent nephrotoxic drugs

Honestly: avoid pending human safety data

What it does

Adipotide (prohibitin-targeting peptide-1 / FTPP) is a proapoptotic peptide that homes to the vasculature of white adipose tissue and triggers programmed cell death of those vessels, starving fat tissue. In primate studies it produced rapid fat loss but dose-dependent renal toxicity (proximal tubule injury). No established human safety or dosing.

Caution

Caution: the defining finding in primate studies was reversible-but-real kidney injury. Without human safety data, any use carries unquantified renal risk.

If used at all, short courses, low doses, and close renal monitoring would be the minimum; but the honest position is that it is not ready for human self-use.

Supply math

Not applicable, no validated human dosing. Research compound only.

Pairs well with

Not recommended for stacking given the safety uncertainty.

Approved drug

Approved weight-loss drugs are far better proven: semaglutide (Wegovy), tirzepatide (Zepbound), orforglipron (Foundayo, oral, 2026), plus phentermine, Qsymia, Contrave and orlistat.

References

PubMed clinicaltrials.gov researchdosing

From the guide, page 15.